344 related articles for article (PubMed ID: 34838310)
1. Omitting axillary lymph node dissection after positive sentinel lymph node in the post-Z0011 era: Compliance with NCCN and ASCO clinical guidelines and Z0011 criteria in a large prospective cohort.
Costaz H; Boulle D; Bertaut A; Rouffiac M; Beltjens F; Desmoulins I; Peignaux K; Ladoire S; Causeret S; Loustalot C; Padeano MM; Vincent L; Jankowski C; Arnould L; Coutant C
Bull Cancer; 2022 Mar; 109(3):268-279. PubMed ID: 34838310
[TBL] [Abstract][Full Text] [Related]
2. [Strategies in case of metastatic sentinel lymph node in breast cancer].
Costaz H; Rouffiac M; Boulle D; Arnould L; Beltjens F; Desmoulins I; Peignaux K; Ladoire S; Vincent L; Jankowski C; Coutant C
Bull Cancer; 2020 Jun; 107(6):672-685. PubMed ID: 31699399
[TBL] [Abstract][Full Text] [Related]
3. Locoregional Recurrence After Sentinel Lymph Node Dissection With or Without Axillary Dissection in Patients With Sentinel Lymph Node Metastases: Long-term Follow-up From the American College of Surgeons Oncology Group (Alliance) ACOSOG Z0011 Randomized Trial.
Giuliano AE; Ballman K; McCall L; Beitsch P; Whitworth PW; Blumencranz P; Leitch AM; Saha S; Morrow M; Hunt KK
Ann Surg; 2016 Sep; 264(3):413-20. PubMed ID: 27513155
[TBL] [Abstract][Full Text] [Related]
4. Effect of Axillary Dissection vs No Axillary Dissection on 10-Year Overall Survival Among Women With Invasive Breast Cancer and Sentinel Node Metastasis: The ACOSOG Z0011 (Alliance) Randomized Clinical Trial.
Giuliano AE; Ballman KV; McCall L; Beitsch PD; Brennan MB; Kelemen PR; Ollila DW; Hansen NM; Whitworth PW; Blumencranz PW; Leitch AM; Saha S; Hunt KK; Morrow M
JAMA; 2017 Sep; 318(10):918-926. PubMed ID: 28898379
[TBL] [Abstract][Full Text] [Related]
5. Which patients with sentinel node-positive breast cancer after breast conservation still receive completion axillary lymph node dissection in routine clinical practice?
Hennigs A; Köpke M; Feißt M; Riedel F; Rezai M; Nitz U; Moderow M; Golatta M; Sohn C; Schneeweiss A; Heil J
Breast Cancer Res Treat; 2019 Jan; 173(2):429-438. PubMed ID: 30315437
[TBL] [Abstract][Full Text] [Related]
6. Role of frozen section in sentinel lymph node biopsy for breast cancer in the era of the ACOSOG Z0011 and IBCSG 23-10 trials.
Lombardi A; Nigri G; Maggi S; Stanzani G; Vitale V; Vecchione A; Nania A; Amanti C
Surgeon; 2018 Aug; 16(4):232-236. PubMed ID: 29329752
[TBL] [Abstract][Full Text] [Related]
7. Non-sentinel axillary tumor burden applying the ACOSOG Z0011 eligibility criteria to a large routine cohort.
Riedel F; Heil J; Feißt M; Rezai M; Moderow M; Sohn C; Schütz F; Golatta M; Hennigs A
Breast Cancer Res Treat; 2019 Sep; 177(2):457-467. PubMed ID: 31236814
[TBL] [Abstract][Full Text] [Related]
8. Retrospectively validating the results of the ACOSOG Z0011 trial in a large Asian Z0011-eligible cohort.
Jung J; Han W; Lee ES; Jung SY; Han JH; Noh DY; Kim Y; Choi HJ; Lee JE; Nam SJ; Lee JW; Kim HJ; Um E; Kim JH; Park S; Cho YU
Breast Cancer Res Treat; 2019 May; 175(1):203-215. PubMed ID: 30715659
[TBL] [Abstract][Full Text] [Related]
9. Impact of the American College of Surgeons Oncology Group (ACOSOG) Z0011 trial on clinical management of the axilla in older breast cancer patients: a SEER-medicare analysis.
Caretta-Weyer H; Greenberg CG; Wilke LG; Weiss J; LoConte NK; Decker M; Steffens NM; Smith MA; Neuman HB
Ann Surg Oncol; 2013 Dec; 20(13):4145-52. PubMed ID: 23959051
[TBL] [Abstract][Full Text] [Related]
10. The effect of omitting axillary dissection and the impact of radiotherapy on patients with breast cancer sentinel node macrometastases: a cohort study following the ACOSOG Z0011 and AMAROS trials.
Ortega Expósito C; Falo C; Pernas S; Pérez Carton S; Gil Gil M; Ortega R; Pérez Montero H; Stradella A; Martinez E; Laplana M; Salinas S; Luzardo A; Soler T; Fernández Montoli ME; Azcarate J; Guma A; Petit A; Benitez A; Bajen M; Reyes Junca JG; Campos M; Ruiz R; Ponce J; Pla MJ; García Tejedor A
Breast Cancer Res Treat; 2021 Aug; 189(1):111-120. PubMed ID: 34089119
[TBL] [Abstract][Full Text] [Related]
11. Economic implications of ACOSOG Z0011 trial application into clinical practice at the European Institute of Oncology.
Mattar D; Di Filippo A; Invento A; Radice D; Burcuta M; Bagnardi V; Magnoni F; Santomauro G; Corso G; Mazzarol G; Viale G; Sacchini V; Galimberti V; Veronesi P; Intra M
Eur J Surg Oncol; 2021 Oct; 47(10):2499-2505. PubMed ID: 34172359
[TBL] [Abstract][Full Text] [Related]
12. [Impact of omission of axillary dissection on adjuvant therapy in patients with metastatic sentinel lymph nodes according to the ACOSOG Z0011 criteria].
Roosen A; Lousquy R; Bricou A; Delpech Y; Selz J; Le Maignan C; Bousquet G; Winterman S; Zelek L; Barranger E
Gynecol Obstet Fertil; 2014 Jun; 42(6):409-14. PubMed ID: 24861437
[TBL] [Abstract][Full Text] [Related]
13. Application of the ACOSOG Z0011 criteria to Chinese patients with breast cancer: a prospective study.
Peng Y; Liu M; Li X; Tong F; Cao Y; Liu P; Zhou B; Liu H; Cheng L; Guo J; Xie F; Yang H; Wang S; Wang C; Chen Y; Wang S
World J Surg Oncol; 2021 Apr; 19(1):128. PubMed ID: 33879180
[TBL] [Abstract][Full Text] [Related]
14. Changes in utilization of axillary dissection in women with invasive breast cancer and sentinel node metastasis after the ACOSOG Z0011 trial.
Tseng J; Alban RF; Siegel E; Chung A; Giuliano AE; Amersi FF
Breast J; 2021 Mar; 27(3):216-221. PubMed ID: 33586201
[TBL] [Abstract][Full Text] [Related]
15. Omission of axillary dissection according to ACOSOG Z0011: impact on adjuvant treatment recommendations.
Aigner J; Smetanay K; Hof H; Sinn HP; Sohn C; Schneeweiss A; Marmé F
Ann Surg Oncol; 2013 May; 20(5):1538-44. PubMed ID: 23389469
[TBL] [Abstract][Full Text] [Related]
16. Expanding Implementation of ACOSOG Z0011 in Surgeon Practice.
Weiss A; Mittendorf EA; DeSnyder SM; Hwang RF; Bea V; Bedrosian I; Hoffman K; Adrade B; Sahin AA; Kuerer HM; Hunt KK; Caudle AS
Clin Breast Cancer; 2018 Aug; 18(4):276-281. PubMed ID: 29100726
[TBL] [Abstract][Full Text] [Related]
17. Age and Receptor Status Do Not Indicate the Need for Axillary Dissection in Patients with Sentinel Lymph Node Metastases.
Mamtani A; Patil S; Van Zee KJ; Cody HS; Pilewskie M; Barrio AV; Heerdt AS; Morrow M
Ann Surg Oncol; 2016 Oct; 23(11):3481-3486. PubMed ID: 27169771
[TBL] [Abstract][Full Text] [Related]
18. Microscopic Extracapsular Extension in Sentinel Lymph Nodes Does Not Mandate Axillary Dissection in Z0011-Eligible Patients.
Barrio AV; Downs-Canner S; Edelweiss M; Van Zee KJ; Cody HS; Gemignani ML; Pilewskie ML; Plitas G; El-Tamer M; Kirstein L; Capko D; Patil S; Morrow M
Ann Surg Oncol; 2020 May; 27(5):1617-1624. PubMed ID: 31820212
[TBL] [Abstract][Full Text] [Related]
19. Analyzing non-sentinel axillary metastases in patients with T3-T4 cN0 early breast cancer and tumor-involved sentinel lymph nodes undergoing breast-conserving therapy or mastectomy.
Riedel F; Heil J; Feisst M; Moderow M; von Au A; Domschke C; Michel L; Schaefgen B; Golatta M; Hennigs A
Breast Cancer Res Treat; 2020 Nov; 184(2):627-636. PubMed ID: 32816190
[TBL] [Abstract][Full Text] [Related]
20. Axillary Dissection and Nodal Irradiation Can Be Avoided for Most Node-positive Z0011-eligible Breast Cancers: A Prospective Validation Study of 793 Patients.
Morrow M; Van Zee KJ; Patil S; Petruolo O; Mamtani A; Barrio AV; Capko D; El-Tamer M; Gemignani ML; Heerdt AS; Kirstein L; Pilewskie M; Plitas G; Sacchini VS; Sclafani LM; Ho A; Cody HS
Ann Surg; 2017 Sep; 266(3):457-462. PubMed ID: 28650355
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
